MGMT and glioma: We believe that the possible reasons include that there are still defects in the current understanding of molecular typing of glioma patients, and the possible effects of IDH, P53, 1P/19Q, PTEN, TERT promoter methylation status and MGMT promoter methylation status on the prognosis of patients are not fully considered in the analysis.